427 related articles for article (PubMed ID: 8622102)
21. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
[TBL] [Abstract][Full Text] [Related]
22. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
[TBL] [Abstract][Full Text] [Related]
24. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
Sweileh WM
Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
[TBL] [Abstract][Full Text] [Related]
25. Cefodizime once daily in the treatment of lower respiratory tract infections.
Piovano CF; Palombini BC; Dagrosa EE; Mendoza F; Facco EB
Arzneimittelforschung; 1997 May; 47(5):674-7. PubMed ID: 9205786
[TBL] [Abstract][Full Text] [Related]
26. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
28. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B.
Pereira GH; Muller PR; Levin AS
Diagn Microbiol Infect Dis; 2007 Jun; 58(2):235-40. PubMed ID: 17350201
[TBL] [Abstract][Full Text] [Related]
29. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.
Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B
Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319
[TBL] [Abstract][Full Text] [Related]
30. An open evaluation of the efficacy and safety of the new macrolide roxithromycin in the treatment of lower respiratory tract infections and pneumonia in Nigerian patients.
Isah AO; Ohaju-Obodo J
West Afr J Med; 1996; 15(2):111-6. PubMed ID: 8855675
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with moxifloxacin in patients with respiratory tract infections.
Faich GA; Morganroth J; Whitehouse AB; Brar JS; Arcuri P; Kowalsky SF; Haverstock DC; Celesk RA; Church DA
Ann Pharmacother; 2004 May; 38(5):749-54. PubMed ID: 15026565
[TBL] [Abstract][Full Text] [Related]
32. Open clinical trial of roxithromycin in patients of Plateau Hospitals, Jos in upper and lower respiratory tract infections.
Okeke EN; Juryit Z; Ikeh EI
West Afr J Med; 1995; 14(4):238-41. PubMed ID: 8634230
[TBL] [Abstract][Full Text] [Related]
33. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections.
Karachalios GN; Houpas P; Tziviskou E; Papalimneou V; Georgiou A; Karachaliou I; Halkiadaki D
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):561-4. PubMed ID: 9799062
[TBL] [Abstract][Full Text] [Related]
34. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
Bassetti M; Righi E; Rosso R; Mannelli S; Di Biagio A; Fasce R; Pallavicini FB; Marchetti F; Viscoli C
Int J Antimicrob Agents; 2006 Dec; 28(6):582-5. PubMed ID: 16979877
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections.
Fayed DF; Dahmash NS; al-Zeer AH; Shibl AM; Huraib SO; Abu-Aisha H
J Chemother; 1996 Dec; 8(6):457-64. PubMed ID: 8981187
[TBL] [Abstract][Full Text] [Related]
37. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
38. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study.
Michalopoulos A; Fotakis D; Virtzili S; Vletsas C; Raftopoulou S; Mastora Z; Falagas ME
Respir Med; 2008 Mar; 102(3):407-12. PubMed ID: 18060758
[TBL] [Abstract][Full Text] [Related]
39. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Peloquin CA; Cumbo TJ; Nix DE; Sands MF; Schentag JJ
Arch Intern Med; 1989 Oct; 149(10):2269-73. PubMed ID: 2508586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
